Memantina Sandoz

Memantine, the active ingredient in Memantina Sandoz, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease and other forms of dementia in adults.

GNH USA supplies Memantina Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantina Sandoz is an NMDA receptor antagonist used in the management of neurodegenerative conditions.

Alzheimer's disease (moderate to severe): helps maintain cognition and daily functioning in patients with advanced disease. Dementia associated with Alzheimer’s: may slow the progression of cognitive decline. Cognitive impairment in Alzheimer’s: can improve memory, attention and reasoning abilities.

Adverse reactions may occur with memantine therapy and are categorized by frequency.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion - Fatigue - Hypertension

Serious or Rare Side Effects: - Seizures - Severe allergic reactions (rash, angioedema) - Hallucinations or psychosis - Cardiac arrhythmias

Memantina Sandoz should be used with attention to patient‑specific risk factors.

Renal impairment: assess kidney function before initiating therapy. History of seizures: monitor closely for increased seizure activity. Concurrent NMDA antagonists: avoid co‑administration to reduce additive toxicity. Pregnancy and lactation: safety not established; use only if benefit outweighs risk. Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and light.

Memantine may interact with several drug classes; interactions are grouped by clinical significance.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism can increase neuro‑psychiatric side effects. - Other NMDA receptor antagonists: additive risk of CNS depression. - Strong CYP450 inducers (e.g., carbamazepine, rifampin): may lower memantine plasma concentrations.

Moderate Interactions (Monitor Closely): - Acetylcholinesterase inhibitors (donepezil, rivastigmine): may enhance therapeutic effect. - Diuretics: can increase risk of dizziness or hypotension. - Antihypertensive agents: monitor blood pressure for additive lowering effects.